ORPHA:88
Idiopathic aplastic anemia
Also known as: Idiopathic bone marrow failure
Publications
471
69.3th percentile
Trials
2
Interventional, condition-specific
Researchers
1,380
Distinct authors in sample
Gene link
NBN
Limited
Readiness
4/6
Stages with a signal
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0012197
- MeSH:C538494
- UMLS:C0348890
- NCIT:C61230
Additional Mondo synonyms (2)
idiopathic aplastic aplasia · idiopathic bone marrow failure
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Limited — NBN
- LiteraturePresent
471 matched papers (217 in last 10 years) Source
- Phenotype characterisedPresent
12 HPO annotations (e.g. Gingival bleeding; Epistaxis; Pancytopenia) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
2 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Possibly — only limited evidence so far for NBN.
GenCC classification: Limited.
Phenotypes (Monarch / HPO)
12
Associated phenotypes · MONDO:0012197
- Gingival bleeding
- Epistaxis
- Pancytopenia
- Autoimmune antibody positivity
- Thrombocytopenia
Showing 5 of 12 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
4
Drugs / clinical candidates · MONDO_0012197
- ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)·phase 2
- CYCLOSPORINE·phase 2
- ELTROMBOPAG·phase 1 2
- RUXOLITINIB·phase 1 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
471
471 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
471 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
217 in the last 10 years · high confidence · 69.3th percentile (publications denominator)
Phrase hits: 459 · MeSH hits: 0
Who's working on it?
1,380
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Matsuda A8 papers · 2025
Department of Hemato-Oncology, International Medical Center, Saitama Medical University, Saitama, Japan.
Papers in Europe PMC - 02Pagliuca S8 papers · 2024
Hematology and Transplantation Unit, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Papers in Europe PMC - 03Mitani K7 papers · 2025
Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.
Papers in Europe PMC - 04Miyazaki Y7 papers · 2025
Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Papers in Europe PMC - 05Nakao S7 papers · 2025
Department of Cellular Transplantation Biology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Papers in Europe PMC - 06Risitano AM7 papers · 2022
Hematology, Department of Clinical Medicine and Surgery, Federico II University of Naples , Italy.
Papers in Europe PMC - 07Tohyama K7 papers · 2025
Department of Laboratory Medicine, Kawasaki Medical School, Okayama, Japan.
Papers in Europe PMC - 08Kawabata H6 papers · 2025
Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Papers in Europe PMC - 09Kurokawa M6 papers · 2025
Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Papers in Europe PMC - 10Ozawa K6 papers · 2025
Division of Hematology, Jichi Medical University, Tochigi, Japan.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
2
interventional trials for this specific condition
2 interventional trials matched this specific condition name; 2 currently recruiting in our sample. 255 trials are registered for aplastic anemia, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 28 July 2026
2 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 84.5th percentile).
high confidence · 84.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
2 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05419843·NOT YET RECRUITING·Up-front Matched Unrelated Donor Transplantation in Pediatric Patients With Idiopathic Aplastic Anemia
Not reviewed·Conditions: Idiopathic Aplastic Anemia · Severe Aplastic Anemia · Moderate Aplastic Anemia Requiring Transfusions·Matched via name phrase
- NCT05126849·RECRUITING·Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression
Not reviewed·Conditions: Refractory Idiopathic Aplastic Anemia · Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation·Matched via name phrase
Broader category: aplastic anemia
255
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06412497·RECRUITING·MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
Not reviewed·Conditions: Severe Aplastic Anemia · Acquired Amegakaryocytic Thrombocytopenia · Acquired Pure Red Cell Aplasia · Paroxysmal Nocturnal Hemoglobinuria·Matched via name phrase
- NCT06517641·RECRUITING·Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
Not reviewed·Conditions: Severe Aplastic Anemia·Matched via name phrase
- NCT07548671·NOT YET RECRUITING·Enarodustat + CsA vs CsA in Newly Diagnosed TD-NSAA
Not reviewed·Conditions: Transfusion-dependent Non-severe Aplastic Anemia·Matched via name phrase
- NCT07552506·NOT YET RECRUITING·Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin
Not reviewed·Conditions: Aplastic Anaemia (AA) · Allogeneic Haematopoietic Stem Cell Transplantation · Ovarian Insufficiency·Matched via name phrase
- NCT06430788·RECRUITING·A Study of Emapalumab for Pediatric Aplastic Anemia
Not reviewed·Conditions: Aplastic Anemia · Cytopenia · Hypocellular Marrow·Matched via name phrase
- NCT07078721·NOT YET RECRUITING·Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia
Not reviewed·Conditions: Aplastic Anemia Idiopathic·Matched via name phrase
- NCT05031897·RECRUITING·Two Step Haplo With Radiation Conditioning
Not reviewed·Conditions: Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Adult T-Cell Leukemia/Lymphoma · Aplastic Anemia·Matched via name phrase
- NCT04304820·RECRUITING·Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)
Not reviewed·Conditions: Severe Aplastic Anemia·Matched via name phrase
- NCT06769568·NOT YET RECRUITING·Reduced-dose Conditioning Regimen Containing TBI in HSCT Treating Elderly Patients With Aplastic Anemia
Not reviewed·Conditions: Aplastic Anaemia · HSCT · TBI · Old Age·Matched via name phrase
- NCT06802055·RECRUITING·Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A
Not reviewed·Conditions: Aplastic Anaemia·Matched via name phrase
- NCT06516484·NOT YET RECRUITING·Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm Study
Not reviewed·Conditions: Aplastic Anemia·Matched via name phrase
- NCT07499284·RECRUITING·A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia
Not reviewed·Conditions: Aplastic Anaemia·Matched via name phrase
- NCT07572084·NOT YET RECRUITING·Romiplostim N01 in Chemoradiotherapy-induced Aplastic Anemia
Not reviewed·Conditions: Aplastic Anemia·Matched via name phrase
- NCT07001254·NOT YET RECRUITING·UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia
Not reviewed·Conditions: Aplastic Anemia·Matched via name phrase
- NCT06633328·RECRUITING·CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia
Not reviewed·Conditions: Aplastic Anemia·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 12 · after dedupe 12 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 12 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (12)
- isrctn·ISRCTN16463547·Recruiting·CRISTAL-APC - a trial of chemokine receptor inhibition for patients with pancreatic cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN66357938·Recruiting·Testing the addition of new treatments to standard treatment in prostate cancer that has spread to other areas of the body
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN62420110·No longer recruiting·A study of selicrelumab (RO7009789) in combination with atezolizumab in participants with locally advanced and/or metastatic solid tumors
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14251143·No longer recruiting·A trial evaluating the effectiveness of combining standard R-CHOP treatment with acalabrutinib in patients with newly diagnosed diffuse large B-cell lymphoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN45319897·No longer recruiting·A study to evaluate the safety, tolerability, processing by the body, and antitumor activity of inavolisib and paclitaxel
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN70443938·No longer recruiting·Stem cell transplantation for chronic obstructive pulmonary disease treatment
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN55111436·No longer recruiting·A double-blind randomised trial to compare oral azacitidine (CC-486) with placebo in adults with acute myeloid leukaemia and myelodysplasia who are undergoing allogeneic stem cell transplantation
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11965217·No longer recruiting·A trial to assess whether the addition of atezolizumab to current standard treatment for patients with relapsed or refractory Diffuse Large B-Cell Lymphoma, who are not able to have high dose therapy, improves survival outcomes
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN74072945·Stopped·A research study looking at faecal transplant as a treatment for ulcerative colitis, and the best way to use it in patients with the condition
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN71070888·No longer recruiting·Scheduling nabpaclItaxel with gemcitabine (SIEGE)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18931678·No longer recruiting·Clinical trial for the treatment of pulmonary alveolar proteinosis by inhalation of recombinant human granulocyte-macrophage colony stimulating factor (GMCSF)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN22201583·No longer recruiting·Treating interstitial pneumonia with the addition of co-trimoxazole
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Idiopathic aplastic anemia — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Idiopathic aplastic anemia" OR "Idiopathic bone marrow failure" OR "idiopathic aplastic aplasia") OR ("NBN syndrome" OR "NBN-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Idiopathic aplastic anemia" OR "Idiopathic bone marrow failure" OR "idiopathic aplastic aplasia"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 2 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"aplastic anemia"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T12:22:32.071Z
